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Abstract 
A number of neurotoxic chemicals induce accumulation of neurofilaments in 
axonal swellings that appear at varying distances from the cell body. This 
pathology is associated with axonal degeneration of different degrees. The 
clinical manifestation is most commonly that of a mixed motor–sensory 
peripheral axonopathy with a disto-proximal pattern of progression, as in cases 
of chronic exposure to n-hexane and carbon disulfide. It has been demonstrated 
that protein adduct formation is a primary molecular mechanism of toxicity in 
these axonopathies, but how this mechanism leads to neurofilament 
accumulation and axonal degeneration remains unclear. Furthermore, little is 
known regarding the mechanisms of neurofilamentous axonopathy caused by 
3,3’-iminodipropionitrile, an experimental toxin that induces proximal axon 
swelling that is strikingly similar to that found in early amyotrophic lateral 
sclerosis. Here we review  the available data and main hypotheses regarding 
the toxic axonopathies and compare them with the current knowledge of the 
biological basis of neurofilament transport. We also review recent studies  
addressing the question of how these axonopathies may cause axonal 
degeneration. Understanding the mechanisms underlying the toxic 
axonopathies may provide insight into the relationship between neurofilament 
behaviour and axonal degeneration, hopefully enabling the identification of new 
targets for therapeutic intervention. Because neurofilament abnormalities are a 
common feature of many neurodegenerative diseases, advances in this area 
may have a wider impact beyond toxicological significance. 
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 INTRODUCTION 
 
Neurofilamentous axonopathies are a major issue in experimental and clinical 
neurotoxicology [1]. In these pathological conditions, abnormal accumulation of 
neurofilaments is found in axonal swellings that occur at varying distances from 
the cell body [2–6]. In some instances, neurofilament inclusions are also 
observed in the cell perikarya [7–9]. Abnormal neurofilament accumulation also 
frequently occurs in several different neurodegenerative diseases [10–13], and 
the pathological features of toxic and neurodegenerative conditions may be 
remarkably similar, suggesting the existence of similar or coincident 
mechanisms of pathogenesis. Thus, neurofilamentous axonopathies are also of 
interest in the area of neurodegenerative pathogenesis.  
 
The initial focus of this review will be the current understanding of neurofilament 
biology. Then the neurofilamentous axonopathies and the known mechanisms 
of toxicity of several major causative agents will be discussed. The final aim will 
be to provide an overview of recent studies that help to illuminate two major 
unresolved issues: the identity of the key mechanisms responsible for 
neurofilament accumulation, and the relationship between neurofilament 
accumulation and axonal degeneration. 
 
NEUROFILAMENT COMPOSITION, TRANSPORT AND REGULATION 
 
Neurofilaments are the intermediate filaments found in neurons, with a typical 
diameter of 10 nm (i.e. diameter between that of the wider microtubules and the 
narrower actin filaments; for review see [10, 12]). They are heteropolymer 
chains containing diverse combinations of intermediate filament proteins, 
including the three major subunits, which are termed neurofilament-high (NF-H), 
-medium (NF-M) and -low (NF-L), according to their apparent molecular weights 
determined by gel electrophoresis. These three proteins are type IV 
intermediate filament proteins, a family of cytoskeletal proteins [14] that include, 
among others, the epithelial keratins (types I and II), the widely expressed 
vimentin (type III) and the nuclear lamins (type V). Another type IV intermediate 
filament protein, alpha-internexin [15], and a type III protein, peripherin [16], 
also assemble into neurofilaments and are currently regarded as additional 
neurofilament subunits [17]. The subunit composition of the neurofilament 
varies according to the neuron cell type, species and developmental stage [12]. 
The neurofilament cytoskeleton controls axonal calibre, which directly 
determines the electrical conduction velocity of the axon [12].   
 
Neurofilaments are transported towards the axon terminal within the ‘slow 
component-a’ of axonal transport, with rates in the range of 0.3–3.0 mm/day 
[18]. This range was determined from classical radioisotopic pulse-labelling 
experiments in which labelled neurofilament proteins were identified at several 
different time points and distances from the cell bodies after injection of a 
radioactive amino acid into the region of the neuronal soma [19, 20]. Such 
experiments provided evidence of a wave of labelled neurofilament proteins 
moving along the axon. However, the nature of the transport and the form of the 
 transported neurofilaments were subjects of intense debate until a clearer 
picture started to emerge at the beginning of this century.  
 
The currently accepted theory of neurofilament transport (Figure 1) is the stop-
and-go theory [18], according to which the slow overall rate of transport 
measured by the classic experimental approach in mature axons is the result of 
rapid, infrequent and asynchronous movement of neurofilament polymers in 
both directions, anterograde (from the cell body to the axon terminal) and 
retrograde (towards the cell body), as supported by experimental evidence [21–
23]. Each individual filament may move in either direction but has a slight 
preference for anterograde movement, and spends most of the time at rest in a 
stationary position. This behaviour determines the slow anterograde 
characteristics of the overall transport even though each discrete anterograde 
and retrograde movement occurs at the rate of fast axonal transport (2–5 μm/s, 
equivalent to 200–400 mm/day). One remaining point of debate is whether all 
neurofilaments may move at any time point, or whether a highly stable 
stationary cytoskeleton is formed in mature axons [24, 25]. Neurofilament 
movements proceed by sliding on microtubule tracts using the common kinesin 
(plus-end directed, anterograde in axons) and dynein (minus-end directed, 
retrograde in axons) motor proteins [26–29]. The interaction of neurofilaments 
with motor proteins and the factors controlling these interactions are not clearly 
understood [11]. The stop-and-go theory is supported by mathematical 
modelling studies which assume six possible states for neurofilament polymers 
(Fig. 1B) and successfully predict cytoskeletal behaviour as a function of the 
transition rates between each state [25, 30, 31]. Nevertheless, it has been 
argued that other mechanisms, including diffusion and axonal growth, need to 
be taken into account to fully explain axon cytoskeletal dynamics given the 
diversity of individual or animal anatomy, cell types and developmental stages 
[32].  
 
Neurofilament protein expression is highly regulated at the gene expression and 
post-transcriptional levels [13]. In addition, neurofilament proteins are highly 
modified at the post-translational level [12]. The most extensively studied 
modification is phosphorylation. Neurofilaments are extensively phosphorylated, 
and their phosphorylation status varies as a function of cell type, location within 
the neuron and developmental stage. In addition, abnormal distribution patterns 
of neurofilament phosphorylation are a common finding in many human 
neurodegenerative diseases and experimental animal models [33, 34]. Changes 
in neurofilament phosphorylation have long been considered to determine 
axonal growth, neurofilament transport and neurofilament stability; however, 
conclusive proof of this has remained elusive and conflicting data have 
emerged. Thus the roles of neurofilament phosphorylation remain unclear [11, 
12, 34]. 
 
Extra-neuronal factors may regulate neurofilament behaviour. It has been 
demonstrated that myelinating Schwann cells locally modulate neurofilament 
phosphorylation, axonal calibre and slow axonal transport [35–37]. It has been 
suggested that this regulation is mediated by the myelin-associated glycoprotein 
[38], but the mechanisms involved are not understood [12, 39]. Glutamate 
receptors have also been highlighted as potential determinants of neurofilament 
transport [40, 41]. 
 
NEUROFILAMENT PATHOLOGY AND NEURODEGENERATIVE DISEASES 
 
Abnormalities in neurofilament expression, transport and regulation have been 
identified in several neurodegenerative diseases. A pathogenic role of these 
abnormalities has been supported by the identification of a number of mutations 
in the genes encoding neurofilament and neurofilament-associated proteins as 
causes of neurological disease. As shown in Table 1, pathogenic mutations in 
these genes have been identified for amyotrophic lateral sclerosis [42, 43], 
other lower motor neuron diseases [44], Charcot-Marie-Tooth disease [45, 46] 
and spastic paraplegias [47]. The relationship between neurofilaments and 
neurodegenerative pathogenesis has been assessed (for reviews see [11–13, 
34, 48–52]). 
 
 
TOXIC NEUROFILAMENTOUS AXONOPATHIES 
 
About 50 single chemical entities or families of similar chemicals have been 
unequivocally or strongly associated with human peripheral neuropathy [53]. Of 
these, at least a dozen involve significant changes in neurofilament distribution 
(Table 2). Other agents that cause similar effects have only been identified in 
experimental animal studies. Some clinically irrelevant agents are nevertheless 
actively studied because their mechanisms of action may be important for 
understanding human pathologies. For several axonopathy-inducing agents, the 
neurofilament effect predominates as the main pathological feature. These 
agents include, among others, n-hexane and related compounds, carbon 
disulfide and related compounds, and 3,3’-iminodipropionitrile (IDPN). The 
compounds related to n-hexane include its toxic metabolite (2,5-hexanedione), 
aliphatic analogues (methyl-n-butyl ketone, 3,4-dimethyl-2,5-hexanedione and 
3-methyl-2,5-hexanedione) and aromatic analogues (1,2-diethylbenzene, 1,2-
diacetylbenzene and 1,2,4-triethylbenzene) [54, 55]. N,N-diethyldithiocarbamate 
and bis(diethylthiocarbamoyl)disulfide (disulfiram)  are related to carbon 
disulfide [56]. A derivative of IDPN that causes the same effects, N-hydroxy-
IDPN, has also been identified [57]. 
 
The neurotoxicity of n-hexane was discovered in industrial settings in which the 
chemical was used as a solvent in poorly ventilated rooms, including shoe and 
furniture factories. In many countries, current workplace regulations have 
succeeded in reducing exposure [58] thus diminishing the incidence of the 
disease. However, recent data suggest that subclinical neurotoxic effects may 
occur with exposure to subThreshold Level Values [59]. In the overt cases, the 
clinical picture is that of a symmetrical sensory–motor neuropathy progressing 
in a disto-proximal sequence. Peripheral nerve biopsies show paranodal axonal 
swellings, filled with neurofilaments, and distal axonal degeneration. Long tracts 
in the central nervous system may also be affected. An aggressive progression 
of the n-hexane neuropathy is observed in cases of high exposure to the 
solvent resulting from substance abuse (e.g. glue sniffing). Workers exposed to 
the related solvent methyl-n-butyl ketone develop similar clinical and 
 pathological signs. A very similar neuropathy is also caused by a chemically 
unrelated solvent, carbon disulfide, used in the vulcanized rubber, rayon fibre 
and other industries. Carbon disulfide exposure also results from its release 
from disulfiram (Antabuse), used for alcohol aversion therapy, and from N,N’-
diethyldithiocarbamate, which has a wide range of agricultural and industrial 
uses [56]. The n-hexane and carbon disulfide neuropathies have been 
extensively studied in animal models that accurately reproduce the clinical and 
pathological findings in humans. In addition, animal studies have characterized 
the similar axonopathies caused by several chemical analogues for which no 
cases of human exposure have been described. These human and 
experimental data have been reviewed [54, 60, 61]. Another similar axonopathy 
is that caused by acrylamide; it has been observed in humans and is 
successfully reproduced in experimental animals. The acrylamide axonopathy 
resembles that caused by n-hexane, but with more prominent axonal 
degeneration and less neurofilament accumulation [62]. Acrylamide has 
received considerable attention since the discovery of its generation during 
cooking [63]. 
 
Humans are unlikely to be exposed to significant amounts of IDPN, but the 
axonopathy caused by this chemical in experimental animals is of great 
theoretical interest. IDPN was initially tested in animals as an analogue of beta-
aminopropionitrile, the first proposed causative agent of lathyrism. Rodents 
exposed to this compound developed a prominent hyperactivity syndrome [64] 
later found to be caused by its toxic action on the vestibular sensory hair cells, 
leading to loss of balance and sense of gravity [65–67]. However, the initial 
pathological studies revealed that it also causes proximal neurofilamentous 
axonopathy [2]; that is, neurofilament-filled swellings of the proximal axon 
segments. As stated by Carpenter who first described the axonal pathology of 
amyotrophic lateral sclerosis in 1968 [68], “the spheroids produced by IDPN 
have a striking morphological similarity, both at light and electron microscopy 
levels, to the spheroids of motor neuron disease”. 
 
MECHANISMS UNDERLYING TOXIC NEUROFILAMENTOUS 
AXONOPATHIES 
 
Findings by several groups during the 1980s and 1990s (for reviews see [54, 
60, 61, 69, 70]) led to well-supported hypotheses to explain the initial 
mechanisms of neurotoxic action of n-hexane and its aliphatic analogues. On 
the basis of these hypotheses, all these neurotoxic conditions were categorized 
as γ-diketone axonopathies (Fig 2A). A similar mechanism of neurotoxic action 
is now well accepted for carbon disulfide (Fig 2B). More recently, aromatic 
compounds have also been shown to cause similar effects to n-hexane, and 
their study have added support to the γ-diketone hypothesis [55, 71, 72]. n-
Hexane and methyl-n-butyl ketone, which are relevant in occupational settings, 
are substrates of microsomal activities that transform them to the γ-diketone, 
2,5-hexanedione. Considerable data support the conclusion that the gamma 
spacing of the two carbonyl compounds in 2,5-hexanedione is critical to the 
generation of neurofilamentous axonopathy. Analogues such as 2,4-
hexanedione which do not keep the γ-diketone structure are not neurotoxic (Fig 
2C). The same is true for the aromatic analogues: the γ-diketone 1,2-
 diacetylbenzene is active and the δ-diketone 1,3-diacetylbenzene is not [71, 72]. 
It has been demonstrated that these γ-diketones covalently bind to amine 
groups in proteins, with a particularly strong affinity for ε-amino groups of 
lysines, generating 2,5-dimethyl-pyrrole adducts. It is widely accepted that 
pyrrole adduct formation is a necessary step for the axonal effects of γ-
diketones [70]. The next proposed step is oxidation of the pyrrolyl adduct; this 
generates a protein-bound electrophile which reacts with protein nucleophiles to 
result in covalent cross-linking of proteins. Available data demonstrate the 
ability of the γ-diketones to cause protein cross-linking, including neurofilament–
neurofilament cross-links. Nevertheless, the relevance of this step to 
neurofilament accumulation and axonal degeneration is still debatable [73]. Like 
γ-diketones, the neurotoxic properties of carbon disulfide seem to be due to the 
ability to form protein adducts and cross-links (Fig 2B). 
 
One problem with the cross-linking hypothesis is that this mechanism may 
operate on many proteins but the γ-diketones produce quite selective 
neurotoxicity. However, two explanations have been proposed. First, not all 
proteins are equally susceptible to cross-linking, as the abundance of lysines in 
the protein and the chemical environment of each lysine ε-amino group in the 
protein determine the likelihood of cross-linking [70, 72]. Secondly, 
neurofilaments are among the proteins with the longest half-lives in the body; 
that is, they have a lower turnover rate and are thus more likely to accumulate 
in an abnormally modified form. This explanation has received support from 
experimental and human studies demonstrating cross-linking of erythrocyte 
spectrin due to γ-diketone and carbon disulfide exposure. This finding was 
predicted because erytrocyte spectrin has also a low turnover rate since it has 
no turnover during the average erythrocyte circulation of 120 days [69]. 
 
The conclusion that protein adduction is a key step in the γ-diketone and carbon 
disulfide axonopathies led to the unified theory of pathogenesis that included 
protein adduction as the common cause of chemically induced axonal 
neuropathies [74]. The theory included the proposal that IDPN is metabolized to 
reactive metabolites able to generate protein adducts [75]; this theory has 
received some support [57, 76–78] but has not been proven. In fact, in contrast 
to the n-hexane analogues and carbon disulfide, the mechanism of toxicity of 
IDPN remains unclear. In general, the hypothesis that protein adduction is a 
necessary step in all cases of chemically induced neurofilament accumulation 
remains unproven. Nevertheless, protein adduct formation has been proposed 
as a major molecular mechanism in neurotoxicity including, but not restricted to, 
neurofilamentous axonopathies [70]. 
 
Two major differences were initially noted between the n-hexane/carbon 
disulfide and the IDPN axonopathies which were thought to reveal key aspects 
of the mechanisms that generate lesions and their final consequences. The first 
difference was the location of the neurofilament accumulations, which were 
found in the proximal segments of axons in IDPN but distally in n-hexane and 
carbon disulfide axonopathies. It was initially thought that proximal and distal 
axonopathies were two different disease conditions with different mechanisms 
of action. However, n-hexane analogues (3,4-dimethyl-2,5-hexanedione and 
1,2-diacetylbenzene) that cause swelling in the proximal axon segments have 
 been identified [4, 71, 72, 79]. Another analogue, 3-methyl-2,5-hexanedione, 
was found to cause accumulation of neurofilaments throughout the nerve but 
more frequently in intermediate axonal regions [5]. Other studies also 
demonstrated changes in the precise location of the neurofilament 
accumulations depending on the exposure rate or the experimental animal 
species [80]. As a result it is now widely accepted that the different locations of 
the neurofilament accumulations are not determined by different mechanisms of 
neurotoxic action. 
 
The second major difference noted between the n-hexane/carbon disulfide and 
the IDPN axonopathies was that the accumulation of neurofilaments was 
associated with axonal degeneration and muscular weakness in the former (see 
above), whereas no degeneration or weakness was evident with IDPN [81]. 
This raised the issues of whether the neurofilament effect is the cause of the 
degeneration effects, or whether they are different phenomena caused by 
common molecular mechanisms or whether they are caused by different 
mechanisms. Several studies have shown that the γ-diketones that more rapidly 
cause protein cross-linking tend to cause more proximal swellings, and are 
more neurotoxic in terms of functional deficits [4, 79, 82, 83], suggesting a link 
between them. However, the features of IDPN axonopathy are not consistent 
with the conclusion that agents that cause more proximal axonopathies are 
functionally more neurotoxic. According to LoPachin and Lehning [84], 
chemicals that lead to axonal swelling also cause axonal atrophy, and it is this 
atrophy that is directly responsible for the loss of function resulting in clinical 
muscular weakness. However, others have concluded that swelling and atrophy 
are two aspects of the same phenomenon affecting the axon, neurofilament 
redistribution, and that it is axonal degeneration rather than either of these 
morphological features that leads to the neurological deficits [85]. This 
conclusion is supported by several experiments of the effects of chronic IDPN 
exposure which show prominent axonal swelling and atrophy without apparent 
functional deficits [66, 81]. Thus how axonal degeneration is induced and how 
this relates to the alterations in neurofilament transport or distribution are key 
issues that need to be addressed. 
 
NEUROFILAMENT TRANSPORT AND THE TOXIC NEUROFILAMENTOUS 
AXONOPATHIES 
 
The ultimate mechanisms that cause accumulation of neurofilaments remain to 
be identified. In the first description of the IDPN proximal axonopathy, Chou and 
Hartmann [2] introduced the concept of ‘axostasis’ to explain neurofilamentous 
axonopathies. This implied the movement of the axoplasm  from the proximal to 
the distal axon segments, and the appearance of axonal swelling following 
alterations in axonal transport. Identification of the different protein constituents 
of the cytoskeleton and of the different rates of transport led to the proposal that 
agents causing neurofilamentous axonopathies do so by specifically altering 
neurofilament transport. Consistent with this hypothesis, IDPN was found to 
cause a decrease in this transport [20], and unaltered synthesis and delivery 
into the axon from the cell body in combination with decreased axonal 
movement was assumed to cause the proximal axonopathy. The effect of the γ-
diketones on neurofilament axonal transport was more difficult to determine, as 
 it was reported to be accelerated by 2,5-hexanedione [86] and decreased by 
3,4-dimethyl-2,5-hexanedione [87]. In any case, the cross-linking hypothesis 
postulated that cross-linked neurofilaments would accumulate because they 
would not be transported across the axonal constriction at the nodes of Ranvier, 
thus explaining the localization of the swellings proximal to the nodes (see [88]). 
According to this view, the swellings would consist of cross-linked 
neurofilaments unsuitable for transport. Although this prediction had not been 
experimentally demonstrated, it gained wide acceptance because it was 
consistent with the theory that neurofilament transport includes only 
anterograde movements.  
 
However, this view is much more difficult to accommodate within the currently 
accepted stop-and-go theory of neurofilament transport, in which, as explained 
above, the behaviour of the neurofilaments is much more dynamic. If the slow 
axonal transport is the overall result of rapid forward and backward movements 
and if neurofilament cross-linking causes removal of the altered subunits from 
the transportable pool, the generation of focal swellings is not easy to explain. 
Modelling studies indicate that small changes in the rates governing the state 
transitions shown in Fig 1B are sufficient to cause overt changes in 
neurofilament behaviour, and reveal the rate at which neurofilaments reverse 
their direction of movement as the most likely parameter governing the overall 
rate of their transport and distribution along axons [31]. A first possible 
conclusion from these results is that similar neurofilament swellings may result 
from similar changes in neurofilament dynamics irrespective of the initial trigger. 
Rather than a passive accumulation of cross-linked neurofilaments, the axonal 
swellings in the γ-diketone and carbon disulfide axonopathies may be the 
consequence of altered state transition rates. In these cases, protein adduction 
and perhaps cross-linking would lead to the altered neurofilament behaviour. 
However, causes other than adduction and cross-linking can be hypothesized in 
the case of IDPN or neurodegenerative-associated axonopathies. A second 
possible conclusion is that any factor involved in the regulation of neurofilament 
transport, not only the neurofilaments, could generate the pathology.  
 
Experimental animal studies have begun to address toxic neurofilamentous 
axonopathies in the light of recent understanding of neurofilament biology. Sabri 
et al. [89] examined the impact of exposure to the axonopathy-inducing agent  
1,2-diacetylbenzene on the neuronal content of kinesin, dynein, NF-M and tau, 
and observed a number of alterations that were not found after exposure to the 
non-neurotoxic isomer 1,3-diacetylbenzene. In a more detailed analysis, Zhang 
et al. [90] examined protein–protein interactions in co-sedimentation assays 
using microtubules and neurofilaments prepared from rats exposed to 2,5-
hexanedione. These authors observed no relevant changes in the distribution of 
neurofilaments, alpha- or beta-tubulins, kinesins (KIF1A, KIF3 and KIF5), 
dynein or the dynein-associated protein dynactin. By contrast, the microtubule 
preparations showed a substantial reduction in the co-sedimentation of the 
microtubule-associated proteins (MAPs) MAP1A, MAP1B heavy chain, MAP2 
and tau, suggesting that the γ-diketones may cause the axonopathy by 
selectively impairing the binding of MAPs to microtubules. Furthermore, the 
candidate target Spna2, also known as α-II spectrin, was identified by proteomic 
analysis of 2,5-hexanedione-exposed animals [ 91]. This led to the hypothesis 
that calpain- and/or caspase-mediated proteolysis of this structural protein is 
central to the development of axonal swellings in the γ-diketone axonopathy. 
However, a study of the toxicity of 1,2-diacetylbenzene in Spna2 mutant mice 
lacking a calpain- and/or caspase-sensitive domain did not support the 
hypothesis [92]. Soler-Martín et al. [93] hypothesized that the IDPN axonopathy 
could be explained by a shift in the dominant direction of transport, from 
anterograde to retrograde (a rightward shift in the equilibrium state in Fig 1B). If 
this were the case, the proximal neurofilament-filled swellings would contain not 
only neurofilaments from the cell body, but also neurofilaments recruited from 
more distal axon segments. Also, the proximal accumulation of neurofilaments 
would be associated with a wave of loss of neurofilaments progressing in a 
disto-proximal direction. To test this prediction, the authors examined distal 
motor axons from IDPN-exposed rats to determine neurofilament content. The 
results showed a significant loss of neurofilaments at the motor endplate, but 
not at the more distal axon segments. Of note, these results did not confirm the 
hypothesis, as endplate loss can be attributed not only to retrograde transport 
but also to lack of delivery and local proteolysis; synaptic terminals are sites of 
neurofilament degradation by calcium-activated proteases [94, 95]. However, 
the results do not disprove the hypothesis either, because the possibility that 
the mature axon contains a highly stable stationary neurofilament cytoskeleton, 
with only a small fraction of neurofilaments undergoing transport [24], would 
mean that the methods used were not sensitive enough to detect a distal to 
proximal movement of the small potentially mobile fraction. In addition, lack of 
sensitivity could be an explanation even if all neurofilaments are available for 
movement [25] but do so at a very low rate in the distal axons evaluated. 
 
AXONAL DEGENERATION AND THE TOXIC NEUROFILAMENTOUS 
AXONOPATHIES 
 
As noted above, the relationship between neurofilamentous pathology and the 
axonal degeneration that occurs in toxic axonopathies has not been 
satisfactorily defined. Because accumulation of neurofilaments was found to be 
prominent and precede axonal degeneration, initially they were attributed a 
causative role. However, IDPN may cause neurofilament accumulation with little 
evidence of neuronal degeneration [66, 81]. To investigate the relationship 
between neurofilaments and axonal degeneration, the effects of the γ-diketones 
and acrylamide were tested in animals lacking axonal neurofilaments. Different 
conclusions were first obtained using the crayfish [96] and the neurofilament-
deficient quail [97], but more convincing data from a transgenic mouse model 
lacking axonal neurofilaments indicated that these cytoskeletal elements are not 
necessary for the development of degenerative axonal changes in these 
axonopathies [98]. Thus, axonal degeneration is likely to occur in parallel to the 
effects on the neurofilament and not subsequently. 
 
Some studies have now begun to search for proteins other than neurofilaments 
that may be the target of axonopathy-inducing chemicals and mediate axonal 
degeneration. By proteomic comparison of the differential effects of the 
neurotoxic 1,2-diacetylbenzene and the non-neurotoxic 1,3-diacetylbenzene, 
Tshala-Katumbay and colleagues [99] identified 22 candidate proteins. Among 
these proteins, they highlighted two as candidates for involvement in nerve fibre 
 degeneration, protein disulfide isomerase and gelsoin, which were found to be 
downregulated by 1,2-diacetylbenzene. Protein disulfide isomerase is a 
chaperone that regulates protein folding; it associates with superoxide 
dismutase, and may play a protective role against the protein aggregation that 
commonly occurs in motor neurons in amyotrophic lateral sclerosis [100]. 
Gelsoin, which has an important role in actin dynamics, is protective against 
excitotoxic and apoptotic neuronal death [101] and is mutated in the familial 
amyloid polyneuropathy type IV [102]. It is interesting that these two proteins 
were also identified by proteomic analysis of the spinal cord of rodents exposed 
to 2,5-hexanedione, thus supporting the conclusion that their loss may be of 
pathogenic significance [91]. The mechanism responsible for this loss remains 
to be elucidated; an initial hypothesis is that these proteins are good targets for 
γ-diketone-induced lysine ε-amino adduction, as predicted by their amino acid 
sequence [91, 99].  
 
Another important question is whether the neurofilament effects may or may not 
be related to later axonal degeneration, even though other more direct 
mechanisms cause the degeneration in the γ-diketone axonopathy. This would 
be especially relevant to understand the significance of accumulation of 
neurofilaments in diseases such as amyotrophic lateral sclerosis. Although 
there is usually little or no axonal degeneration in IDPN-induced proximal 
axonopathy [66, 81], degeneration in this model has been reported [103]. It has 
been speculated that the achievement of a critical mass of accumulated 
neurofilaments or an effect caused by indirect impairment of fast axonal 
transport provide possible links between neurofilamentous axonopathies and 
axonal degeneration. However, the finding that the proximal neurofilament 
accumulations are associated with early loss of neurofilaments at the 
neuromuscular junction [93] highlights an additional link that should be 
investigated. Accumulating evidence supports the notion that amyotrophic 
lateral sclerosis is likely to be a distal axonopathy in which retraction of the 
terminals is a major factor in motor neuron degeneration [104–107] (for a review 
see [108]). Findings of studies in a homologous mouse model of spinal 
muscular atrophy indicate that altered maturation of the cytoskeleton of the pre-
synaptic element probably leads to its degeneration [109]. Thus, the possibility 
that axonal accumulation of neurofilaments is associated with extensive loss at 
the synaptic level should be evaluated in other toxic axonopathies and 
neurodegenerative conditions as a potential mechanism contributing to synaptic 
detachment and subsequent axonal degeneration. 
 
CONCLUSION 
 
Toxic neurofilamentous axonopathies are an important and interesting subset of 
neurotoxic diseases that may be also useful as models for understanding the 
pathogenic mechanisms of neurodegenerative disease. Several decades of 
research have resulted in an extensive description of these disease conditions, 
as well as insight into the mechanisms of toxic action. However, the 
mechanisms underlying neurofilament accumulation and axonal degeneration, 
and the relation between these two phenomena, remain unclear. As 
understanding of the basic biological processes involved in axonal growth, 
 survival and transport increases, toxic axonopathies offer new opportunities for 
understanding pathogenic mechanisms of widespread medical significance. 
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FIGURE LEGENDS 
 
Figure 1. The stop-and-go theory of neurofilament transport. A. According to 
this theory, neurofilaments (orange) move bidirectionally along microtubules 
(yellow). Kinesin motor proteins (blue) move the neurofilaments towards the 
axon tip (anterograde movement), while dynein motor proteins (red) are 
responsible for retrograde movement towards the cell body. The anterograde or 
retrograde sense of the movements are dictated by the orientation of axonal 
microtubules, all of which have their plus ends at the distal side. At any one time 
point, only a small fraction of neurofilaments move, as they spend most of the 
time resting. (Adapted from [18]). B. Schematic representation of the six-state 
model of Li et al. [25] describing the behaviour of neurofilaments according to 
this theory. Each discrete anterograde and retrograde movement occurs at the 
rate of fast axonal transport, which is determined by the velocity of the motor 
proteins. . The rates of transition from one state to another determine the 
behaviour of the neurofilament population, typically described as the slow 
component-a of axonal transport.   
  
  
Figure 2. Axonopathy-inducing  agents, their mechanisms of bioactivation, 
active metabolites and inactive analogues [54, 55, 60, 61, 69]. A. The γ-
diketone 2,5-hexanedione is the common neurotoxic metabolite of the solvents 
n-hexane and methyl-n-butyl ketone. The γ-diketones react with the ε-amino 
groups of lysines to generate pyrrole adducts in many proteins. Oxidation of 
these pyrrole adducts has been shown to cause protein–protein cross-links. B. 
Carbon disulfide generates dithiocarbamate and isothiocyanate adducts on 
proteins, able to generate dithiocarbamate ester and thiourea cross-links 
between proteins. C. The aromatic analogues of n-hexane, 1,2-diethylbenzene 
and 1,2,4-triethylbenzene, are neurotoxic because they generate the aromatic γ-
diketones 1,2-diacetylbenzene and 1,2,4-triacetylbenzene. Isomers that do not 
have a γ-diketone structure are not neurotoxic. 
 
 
 
Table 1 Neurofilament and motor protein mutations in neurodegenerative diseases 
 
Disease   Gene   Gene product    Reference 
 
CMT2A  KIF1B  Kinesin family member 1B   Zhao et al. 2001 [45] 
CMT2  NEFL  Neurofilament light   Mersiyanova et al. 2000 [46] 
SPG10  Kif5A  Kinesin family member 1A (KIF5A)   Wang and Brown 2010 [47] 
LMND  DCTN1  Dynactin subunit p150Glued    Puls et al. 2003 [44] 
ALS  PRPH  Peripherin     Corrado et al. 2011 [43] 
ALS  NFH  Neurofilament heavy chain   Al-Chalabi et al. 1999 [42] 
 
CMT2A, Charcot-Marie-Tooth disease type 2A; CMT2, Charcot-Marie-Tooth disease type 2; SPG10, spastic 
paraplegia type 10; LMND, lower motor neuron disease; ALS, amyotrophic lateral sclerosis. 
 
 
Table 2. Agents associated with peripheral neuropathy that cause significant changes in neurofilament distribution. 
 
In humans 
 
Acrylamide 
Allyl chloride 
Arsenic 
Carbon disulfide 
Dimethylaminopropionitrile 
Diphteria toxin 
Ethylene oxide 
Hexachlorophene 
n-Hexane and its analogues 
Misonidazole 
Organophosphorus compounds 
Piridoxine 
 
In experimental animals 
 
Aluminum chloride 
1,2-Diacetylbenzene 
3,3’-Iminodipropionitrile 
